Health Care • Biotechnology: Pharmaceutical Preparations
$3.42 ▼ -0.06
(-1.72%)
MKT CAP: $58.8M • VOL: 29.7K
52W L $3 52W H $10
ROARABLE / RQD
D • 44/100
PIOTROSKI
4 / 9
VRCA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $35.6M | $7.6M | $5.1M |
| YoY Revenue Growth % | +370.2% | +47.7% | — |
| Gross Profit | — | $5.0M | — |
| Gross Margin % | — | 65.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$12.2M | -$65.9M | -$65.8M |
| Operating Margin % | -34.2% | -80.0% | -80.0% |
| Net Income (GAAP) | -$17.9M | -$76.6M | -$67.0M |
| EBITDA (Normalized) | -$12.2M | -$65.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$17.6M | -$60.9M | -$38.6M |
| Capital Expenditures (CapEx) | $0 | $27.0K | — |
| Free Cash Flow (FCF) | -$17.6M | -$61.0M | -$38.6M |
| FCF Margin % | -49.5% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $30.1M | $46.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $24.7M | -$9.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VRCA.